Back to the drawing board for FDA’s revised quality metrics plan?
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyChemistry, Manufacturing and Controls (CMC)ComplianceNorth AmericaPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/Policy